PolyPid Announces Revolutionary Drug Delivery System
PolyPid, a developer of innovative drug carriers, recently announced the company’s flagship platform – PolyPid, an innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems. The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, proteins, and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.
“PolyPid is a groundbreaking drug carrier that will help pharmaceutical and biotech companies enhance their drugs and meet their challenges,” said Dr. Noam Emanuel, PolyPid’s Chief Technology Officer. “Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopedics, urology, periodontal, anti-cancer/anti-fungal treatments and surgical accessories.”
PolyPid technology makes it possible to entrap a large variety of one or more biologically active molecules, and to release them at a pre-programmed rate for up to several months, all according to the desired clinical rate. During its long-lasting effect, the drug reservoir is fully protected from both biodegradation and hydration.
The first PolyPid-based solution is BonyPid, biodegradable bone void filler that is micro-coated with a PolyPid biodegradable formulation. The coating gradually releases one or more selected antibiotics into its surroundings. Subsequently, the bone void filler scaffold remains and supports bone recovery. Thus, using BonyPid will not change the current method of treatment that used bone grafting. The physician will simply replace the conventional bone void filler with BonyPid to obtain the benefits of conventional bone void filler combined with an effective local drug delivery system.
Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopedics, urology, periodontal, anti-cancer/anti-fungal treatments, and surgical accessories. PolyPid Ltd. is owned by Xenia Venture Capital, private investors, and the founders.
Total Page Views: 1156
